Polskie Radio covers shifts in Florida's market for GLP-1 weight loss drugs during 2025. Little detail is available beyond the topic.
Recap by typeshit. Full story at www.polskieradio.pl.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
Cleveland Clinic notes there's little research and no official guidance on low-dose semaglutide, while trials show far smaller weight loss than standard dosing.
Reuters reports these are the WHO's first global guidelines on obesity in younger kids, and they put lifestyle changes ahead of weight loss drugs.
Loading…